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Abstract
Aims We investigated whether addition of diastolic dysfunction (DD) and longitudinal strain (LS) to Stage B heart failure
(SBHF) criteria (structural or systolic abnormality) improves prediction of symptomatic HF in participants of the SCReening
Evaluation of the Evolution of New Heart Failure study, a self-selected population at increased cardiovascular disease risk re-
cruited from members of a health insurance fund in Melbourne and Shepparton, Australia. Both American Society of Echocar-
diography and European Association of Cardiovascular Imaging (ASE/EACVI) criteria and age-specific Atherosclerosis Risk in
Communities (ARIC) study criteria, for SBHF and DD, and ARIC criteria for abnormal LS, were examined.
Methods and results Inclusion criteria were age ≥60 years with one or more of self-reported ischaemic or other heart dis-
ease, irregular or rapid heart rhythm, cerebrovascular disease, renal impairment, or treatment for hypertension or diabetes for
≥2 years. Exclusion criteria were known HF, or ejection fraction <50% or >mild valve abnormality detected on previous echo-
cardiography or other imaging. Echocardiography was performed in 3190 participants who were followed for a median of 3.9
(interquartile range: 3.4, 4.5) years after echocardiography. Symptomatic HF was diagnosed in 139 participants at a median of
3.1 (interquartile range: 2.1, 3.9) years after echocardiography. ARIC structural, systolic, and diastolic abnormalities predicted
HF in univariate and multivariable proportional hazards analyses, whereas ASE/EACVI structural and systolic, but not diastolic,
abnormalities predicted HF. ARIC and ASE/EACVI SBHF criteria predicted HF with sensitivities of 81% and 55%, specificities of
39% and 76%, and C statistics of 0.60 (95% confidence interval: 0.57, 0.64) and 0.66 (0.61, 0.71), respectively. Adding ARIC DD
to SBHF increased sensitivity to 94% with specificity of 24% and C statistic of 0.59 (0.57, 0.61), whereas addition of ASE/EACVI
DD to SBHF increased sensitivity to 97% but reduced specificity to 9% and the C statistic to 0.52 (0.50, 0.54, P < 0.0001).
Addition of LS to ARIC or ASE/EACVI SBHF criteria had minimal impact on prediction of HF.
Conclusions Age-specific ARIC DD criteria, but not ASE/EACVI DD criteria, predicted symptomatic HF, and addition of age-
specific ARIC DD criteria to ARIC SBHF criteria improved prediction of symptomatic HF in asymptomatic individuals with cardio-
vascular disease risk factors. Addition of LS to ASE/EACVI or ARIC SBHF criteria did not improve prediction of symptomatic HF.
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Introduction
Heart failure (HF) is a complex and progressive clinical
syndrome that results from any structural or functional
impairment of ventricular filling or ejection of blood,1 with a
lifetime risk of 20% to 46%.2 HF may result from disorders
of the pericardium, myocardium, endocardium, heart valves,
or great vessels, or metabolic abnormalities, but most
patients with HF have symptoms due to impaired left ventric-
ular (LV) structure or function.1 The American College of
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Cardiology Foundation and American Heart Association
guideline describes four stages of HF, Stages A and B that
are asymptomatic and Stages C and D that are symptomatic.1
Stage A HF refers to asymptomatic individuals with cardiovas-
cular disease (CVD) risk factors but without structural heart
disease, whereas Stage B HF (SBHF) refers to asymptomatic
individuals with structural heart disease, which may include
any of LV dilatation, LV hypertrophy (LVH), reduced LV ejec-
tion fraction (LVEF), wall motion abnormalities (WMAs), and
moderate or greater aortic or mitral stenosis or regurgita-
tion.3,4 SBHF predicts symptomatic HF,3,4 and its recognition
offers an opportunity to use cardioprotective medication
and/or lifestyle modification to prevent or retard its progres-
sion to symptomatic HF. There has been discussion about
how best to define SBHF with respect to cut-offs for LV di-
mensions, LVH, and LVEF, and whether inclusion of diastolic
dysfunction (DD) and longitudinal strain (LS) as part of SBHF
criteria improves the prediction of symptomatic HF.3–6
Age-related changes in cardiac structure and function are
well recognized, including smaller LV size, greater LVEF, and
lower early diastolic mitral annular tissue Doppler velocities
(TDI e0).7,8 The American Society of Echocardiography and Eu-
ropean Association of Cardiovascular Imaging (ASE/EACVI)
guideline describes normal ranges based on populations with
mean ages ranging from 37 to 50 years,7 whereas the Athero-
sclerosis Risk in Communities (ARIC) study defined 95th per-
centile limits derived from the ARIC study healthy subgroup
aged 67–91 years. In comparison with the ASE/EACVI guide-
lines, ARIC cut points are higher for LVEF, lower for LV end di-
astolic volume indexed to body surface area (LVEDV/BSA), LV
mass (LVM) indexed to height2.7 and TDI septal e0, and similar
for the peak early diastolic mitral flow E/e0 ratio and left atrial
volume (LAV) indexed to BSA.3,7,9,10 In the present study, we
compared the prevalence of SBHF in a community-based co-
hort of individuals aged ≥60 years with CVD risk factors using
ASE/EACVI and ARIC criteria and investigated whether addi-
tion of DD and LS to SBHF criteria improved the prediction
of symptomatic HF. We hypothesized that addition of DD
and LS to SBHF criteria improves the prediction of symptom-
atic HF.
Methods
Study population
The SCReening Evaluation of the Evolution of New Heart Fail-
ure (SCREEN-HF) study was a community-based evaluation of
the use of serum amino-terminal pro-B-type natriuretic pep-
tide to identify individuals with cardiac dysfunction (as
assessed by echocardiography) and increased risk of HF and
other CVD events. The study has been described else-
where,11–13 and participant recruitment and baseline
assessment are described in the Supporting Information. A
flow chart for participant recruitment and follow-up is shown
in Supporting Information, Figure S1. The SCREEN-HF study
was approved by the Alfred Human Research Ethics Commit-
tee, conformed to the ethical standards of the Declaration of
Helsinki, and written informed consent was obtained from all
participants. The study was registered at ClinicalTrials.gov
NCT00400257, NCT00604006, and NCT01581827.
Follow-up
Participants were examined for signs of HF during Visits 2 and
3. Details of symptoms, interim clinical events, and medica-
tion were collected at each visit and also by telephone inter-
view (Supporting Information, Figure S1). In order to capture
all incident cases of HF, a participant was referred to their
cardiologist or to a SCREEN-HF study cardiologist if he or
she reported symptoms consistent with HF or if signs consis-
tent with HF were detected during a study visit, and informa-
tion was requested from the participant’s primary care
provider, physician, and cardiologist. All participant files were
reviewed by a cardiovascular physician, and documentation
of all deaths and other events was requested from hospitals
and the participant’s primary care provider, physician, and
cardiologist. All diagnoses of HF and suspicion of HF were
submitted to adjudication by two HF specialists according to
European Society of Cardiology criteria of 2012.14 When
one adjudicator made a diagnosis of HF and the other did
not, a third HF specialist adjudicated on the presence or ab-
sence of HF. We excluded 23 participants who developed
HF before the echocardiography visit.
Echocardiographic assessment
Cardiac structure and function were assessed using transtho-
racic echocardiography with either a Vivid 7 (n = 2929) or
Vivid i (n = 261) instrument (GE Healthcare, Chicago, Illinois,
USA). Echocardiography was performed according to
ASE/EACVI guidelines.7,9,10,15 Data were stored in raw data
format and analysed offline by two experienced cardiologists.
Interobserver intraclass correlation coefficients (ICCs) for M-
mode measurements were >0.78 for wall thickness, >0.88
for LA diameter, and >0.9 for other M-mode measurements,
≥0.87 for two-dimensional measurements, >0.85 for stan-
dard Doppler measurements except pulmonary vein A wave
velocity, and >0.92 for tissue Doppler measurements.
Intraobserver ICCs were generally higher than for interob-
server ICCs. Pulmonary vein A wave velocity and duration
are not reported because interobserver and intraobserver
ICCs were <0.6.
Left ventricular dimensions were estimated using the two-
dimensional-guided M-mode approach.7 LVM was calculated
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using the two-dimensional area–length method when endo-
cardial definition and alignment in the parasternal short-axis
view were satisfactory and also with the linear method.7
LVM from either method was indexed to BSA and, for LVM
estimated by the linear method, was also indexed to
height2.7.9 LVEF was calculated using the modified Simpson’s
biplane method. Where endocardial definition was poor in
both four-chamber and two-chamber views, the LVEF was vi-
sually estimated, and LV volumes were not calculated. LV re-
gional WMA was identified based on the presence of
hypokinesis, akinesis, or dyskinesis of two or more contiguous
segments of the LV.
Measures of diastolic function were estimated according
to the 2016 ASE/EACVI guideline.10 LAV was calculated using
the biplane method of disks from LA areas measured in the
apical four-chamber and two-chamber views in the frame
prior to mitral valve opening.7 LV inflow was obtained using
pulsed wave Doppler in the apical four-chamber view; peak
early (E) and late (A) diastolic velocities, deceleration time,
and E/A ratio were obtained. Peak early diastolic medial
and lateral mitral annular e0 were measured from pulsed
TDI and E/e0 obtained. Mitral and aortic valve function was
assessed and graded according to American College of Cardi-
ology Foundation guidelines.16 The right ventricle was
assessed according to ASE guidelines.9,17
Longitudinal strain was assessed using speckle-tracking and
EchoPac software (GE Healthcare) when the frame rate was
≥30 frames per cardiac cycle.18 The endocardial border of
the left ventricle was traced in the apical four-chamber and
two-chamber views at end-systole where the region of inter-
est was automatically defined and the integrity of the speckle
tracking was visually assessed and manually corrected if re-
quired. Peak systolic strain in the two views was averaged
to obtain LS. LS was not measured if more than two segments
in either the four-chamber or two-chamber view could not be
tracked. In the setting of a rhythm other than sinus rhythm,
LS measurement was performed using 5 cycles and averaged.
LS is not reported for participants with left bundle branch
block or paced rhythm.
Definitions of Stage B heart failure
ASE/EACVI SBHF criteria were at least one of LVEF <52%
(men) or <54% (women); WMA; LVEDV/BSA >74 mL/m2
(men) and >61 mL/m2 (women); LVM/BSA >115 g/m2
(men) or >95 g/m2 (women), linear method, or
>102 g/m2 (men) or >88 g/m2 (women), area–length
method; and moderate or greater stenosis or regurgitation
of the aortic or mitral valve.7 We examined the effect of
addition of ASE/EACVI DD criteria to this definition: at least
one of septal e0 <7 cm/s; lateral e0 <10 cm/s; septal E/e0
ratio >15; lateral E/e0 ratio >13; average E/e0 ratio >14;
and LAV/BSA >34 mL/m2.10
ARIC SBHF criteria were at least one of LVEF <59% (men)
or <57.4% (women); WMA; LVEDV/BSA >60.2 mL/m2
(men) or >51.9 mL/m2 (women); LVM/height2.7 >45 g/m2.7
(men) or >41.5 g/m2.7 (women), linear method; and moder-
ate or greater stenosis or regurgitation of the aortic or mitral
valve.3 We examined the effect of addition of ARIC DD criteria
to this definition: at least one of septal e0 <4.3 cm/s (men) or
<4.1 cm/s (women); septal E/e0 ratio >14.8 (men) or >17.4
(women); and LAV/BSA >34.2 mL/m2 (men) or >32.4 mL/
m2 (women).3
We also examined the effect of addition of LS to
ASE/EACVI and ARIC SBHF criteria, using ARIC cut points
(>14.7% in men and >15.2% in women) and a cut point
of >18%.5
Statistical analysis
Continuous variables are presented as median (interquartile
range). Categorical variables are presented as percentages.
Differences between groups were tested with Mann–
Whitney U test for continuous variables and χ2 tests for cat-
egorical variables, and statistical significance was interpreted
as a two-tailed P value <0.05. Hazard ratios were calculated
using a semiparametric proportional hazards model for the
subdistribution of the competing risk of death,19 and follow-
up was restricted to 4 years (106 cases) to ensure propor-
tional hazards assumptions were met. Receiver operating
characteristic (ROC) C statistics were estimated from time-
dependent ROC curves for censored event times with the
competing risk of death.20 Analyses were conducted using
Statview 5.0.1 (SAS Institute, Cary, NC, USA) and R.
Results
Baseline clinical characteristics
The baseline characteristics of participants who attended and
those who did not attend for echocardiography are shown in
Supporting Information, Table S1. At the time of echocardiog-
raphy, participants who attended for echocardiography had a
median age of 71 (interquartile range: 67, 77) years, 55%
were male, 89% of men and 94% of women had hyperten-
sion, 20% of men and 15% of women had diabetes, 34% of
men and 37% of women were obese (body mass index
≥30 kg/m2), 49% of men and 39% of women were overweight
(25 < body mass index < 30 kg/m2), 19% of men and 20% of
women had an estimated glomerular filtration rate
<60 mL/min/1.73 m2, 14% of men and 10% of women had
atrial fibrillation (AF), 15% of men and 5% of women had pre-
vious myocardial infarction, and 31% of men and 14% of
women had a history of ischaemic heart disease.
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Echocardiography
Measures of LV and LA structure are shown in Table 1. Ap-
proximately 3% of participants had increased LVEDV/BSA
according to ASE/EACVI criteria, whereas 16% of men and
11% of women had increased LVEDV/BSA according to ARIC
criteria. LVM/BSA was elevated in 16% to 29% of partici-
pants when LVM was estimated by either the area–length
or linear method, according to ASE/EACVI criteria. However,
the proportion with LVH was approximately two-fold higher
when LVM was indexed to height2.7, using either ASE and
European Association of Echocardiography9 or ARIC
criteria.3 Approximately half of participants had elevated
LAV/BSA, with similar proportions according to ASE/EACVI
and ARIC criteria.
Measures of systolic function and valve abnormality are
shown in Table 2. LVEF was reduced in 10.2% of men and
6.3% of women, according to ASE/EACVI criteria, and in
46% of men and 24% of women (36% of men and women),
according to ARIC criteria. LS was measured in only 1401 par-
ticipants (Table 2), who resembled the whole cohort in that
492 (35%) had reduced LVEF according to ARIC criteria.
Among those with LS measurement, abnormal LS was present
in 6% of men and 3% of women according to the ARIC
criteria. LS was abnormal in only 1.8% of men and 1.3% of
women with normal LVEF according to ASE/EACVI criteria
who had LS measurement. These proportions were reduced
to 0.5% of men and women when ARIC criteria were used
to define normal LVEF.
Measures of diastolic LV function, and right ventricular
function, are shown in Table 3. The higher e0 cut point of
the ASE/EACVI criteria caused more than half of participants
to have reduced septal or lateral e0, whereas only 6% of
men and 5.9% of women had reduced septal e0 according
to ARIC criteria. However, similar proportions of participants
had elevated septal E/e0 ratio (6% to 15%) according to
ASE/EACVI and ARIC criteria.
Structural, systolic, and diastolic abnormalities
and incident symptomatic heart failure
The 3190 participants were followed for a median of 3.9
(interquartile range: 3.4, 4.5) years, and symptomatic HF
was diagnosed in 139 participants at a median of 3.1 (inter-
quartile range: 2.1, 3.9) years after echocardiography,
representing an incidence rate of 11.2 per 1000 person
years. Symptomatic HF was diagnosed in 83 participants
in the ambulant setting and in 56 participants on hospital-
ization; 35 diagnosed in the ambulant setting were subse-
quently hospitalized with HF.
The distributions of structural, systolic, and diastolic ab-
normalities according to ASE/EACVI and ARIC criteria are
shown in Figure 1. Higher numbers of participants had
structural abnormality according to ARIC (n = 1390) than
ASE/EACVI criteria (n = 584), reflecting the higher preva-
lence of LVH when LVM was indexed to height2.7 (Table 1).
Moreover, higher numbers of participants had systolic ab-
normality according to ARIC (n = 1167) than ASE/EACVI
criteria (n = 329), reflecting the higher LVEF cut points for
ARIC than ASE/EACVI criteria (Table 2). By contrast, more
participants had diastolic abnormality according to
Table 1 Measures of left ventricular and left atrial structure in men and women
Parameter Men (n = 1762) Women (n = 1428)
Number of measurements (%) Value Number of measurements (%) Value
LVEDD/BSA (mm/m2) 1446 (82%) 26 (24, 28) 1223 (86%) 27 (25, 29)
>Normala >30 mm/m2 165 (11%) >31 mm/m2 179 (15%)
LVEDV/BSA (mL/m2) 1333 (76%) 48 (42, 56) 1036 (73%) 41 (35, 47)
>Normala >74 mL/m2 43 (3.2%) >61 mL/m2 25 (2.4%)
>Normalb >60.2 mL/m2 216 (16%) >51.9 mL/m2 114 (11%)
LVMAL/BSA (g/m2) 927 (62%) 88 (80, 97) 856 (68%) 77 (70, 86)
>Normala >102 g/m2 147 (16%) >88 g/m2 173 (20%)
LVMLIN/BSA (g/m2) 1439 (82%) 95 (80, 110) 1213 (85%) 83 (71, 99)
>Normala >115 g/m2 291 (20%) >95 g/m2 354 (29%)
LVMLIN/height2.7 (g/m2.7) 1439 (82%) 43 (36, 51) 1213 (85%) 42 (35, 51)
>Normalc >48 (g/m2.7) 485 (34%) >44 (g/m2.7) 520 (43%)
>Normalb >45 (g/m2.7) 613 (43%) >41.5 (g/m2.7) 628 (52%)
LAV/BSA (mL/m2) 1682 (95%) 34 (28, 41) 1362 (95%) 32 (26, 39)
>Normala >34.0 mL/m2 848 (50%) >34.0 mL/m2 574 (42%)
>Normalb >34.2 mL/m2 833 (50%) >32.4 mL/m2 657 (48%)
BSA, body surface area; LAV, left atrial volume; LVEDD, left ventricular end diastolic diameter; LVEDV, left ventricular end diastolic volume;
LVMAL, LVM determined by area–length method; LVMLIN, LVM determined by the linear method.
Summary statistics are median (interquartile range) or n (%).
aAmerican Society of Echocardiography and European Association of Cardiovascular Imaging guidelines.7
bAtherosclerosis Risk in Communities study 95th percentile limit.3
cAmerican Society of Echocardiography and European Association of Echocardiography guidelines.9
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ASE/EACVI (n = 2848) than ARIC criteria (n = 1619), largely
reflecting the higher e0 cut points for ASE/EACVI than ARIC
criteria (Table 3).
ARIC structural, systolic, and diastolic abnormalities pre-
dicted HF in univariate and multivariable proportional hazards
analyses, whereas ASE/EACVI structural and systolic, but not
Table 2 Measures of left ventricular systolic function and valve abnormality in men and women
Parameter Men (n = 1762) Women (n = 1428)
Number of measurements (%) Value Number of measurements (%) Value
Systolic function
LVEF (%) 1760 (99.9%) 60 (55, 62) 1427 (99.9%) 60 (58, 63)
<Normala <52% 180 (10.2%) <54% 90 (6.3%)
<Normalb <59% 805 (46%) <57.4% 338 (24%)
LVEF <40% 25 (1.4%) 2 (0.1%)
WMA 145 (8.2%) 32 (2.2%)
LS (%) 792 (45%) 19.3 (17.9, 20.8) 609 (43%) 20.1 (18.8, 21.7)
Abnormal LSb >14.7% 48 (6%) >15.2% 17 (3%)
Aortic stenosis >mild 8 (0.5%) >mild 3 (0.2%)
Aortic regurgitation >mild 6 (0.3%) >mild 7 (0.5%)
Mitral stenosis >mild 0 (0%) >mild 0 (0%)
Mitral regurgitation >mild 19 (1.1%) >mild 12 (0.8%)
Tricuspid regurgitation >mild 23 (1.3%) >mild 29 (2.0%)
Pulmonary regurgitation >mild 7 (0.4%) >mild 10 (0.7%)
Aortic or mitral valve disease >mild 33 (1.9%) >mild 22 (1.5%)
LS, longitudinal strain; LVEF, left ventricular ejection fraction; WMA, wall motion abnormality.
Summary statistics are median (interquartile range) or n (%).
aAmerican Society of Echocardiography and European Association of Cardiovascular Imaging guidelines.7
bAtherosclerosis Risk in Communities study 95th percentile limit.3
Table 3 Measures of left ventricular diastolic function, and right ventricular function, in men and women
Parameter Men (n = 1762) Women (n = 1428)
Number of measurements (%) Value Number of measurements (%) Value
Diastolic function (mitral valve Doppler and TDI measurements)
E/A ratio 1599 (91%) 0.89 (0.74, 1.08) 1343 (94%) 0.87 (0.73, 1.05)
Reduced E/A ratioa ≤0.8 550 (34%) ≤0.8 491 (37%)
Increased E/A ratioa ≥2 11 (0.7%) ≥2 13 (1.0%)
Septal e0 (cm/s) 1598 (91%) 6.5 (5.5, 7.6) 1331 (93%) 6.3 (5.2, 7.4)
Reduced septal e0a <7 cm/s 972 (61%) <7 cm/s 875 (66%)
Reduced septal e0b <4.3 cm/s 96 (6.0%) <4.1 cm/s 78 (5.9%)
Lateral e0 (cm/s) 1590 (90%) 8.5 (7.0, 10.0) 1332 (93%) 7.9 (6.6, 9.3)
Reduced lateral e0a <10 cm/s 1184 (74%) <10 cm/s 1119 (85%)
Septal E/e0 ratio 1565 (89%) 9.5 (7.9, 11.8) 1310 (92%) 10.9 (9.0, 13.3)
>Normal septal E/e0 ratioa >15 119 (7.6%) >15 192 (15%)
>Normal septal E/e0 ratiob >14.8 130 (8.3%) >17.4 84 (6.4%)
Lateral E/e0 ratio 1556 (88%) 7.4 (5.9, 9.2) 1301 (91%) 8.6 (7.1, 10.8)
>Normal septal E/e0 ratioa >13 87 (5.6%) >13 140 (11%)
Average E/e0 ratio 1548 (88%) 8.6 (7.1, 10.4) 1294 (91%) 9.8 (8.3, 12.0)
Increased average E/e0 ratioa >14 85 (5.5%) >14 147 (11.3%)
PV S/D ratio 1496 (85%) 1.4 (1.2, 1.7) 1211 (85%) 1.5 (1.3, 1.7)
Reduced S/D ratioa <1 151 (10%) <1 95 (8%)
Right ventricle
RV dilatation 42 (2.4%) 20 (1.4%)
RV dysfunction 39 (2.2%) 6 (0.4%)
RVSP (mmHg) 691 (39%) 27 (24, 31) 670 (47%) 26 (23, 31)
Increased RVSPc >36 mmHg 73 (10.6%) >36 mmHg 61 (9.1%)
TR max velocity (m/s) 725 (41%) 2.4 (2.3, 2.6) 708 (50%) 2.4 (2.2, 2.6)
Increased TR velocitya >2.8 m/s 74 (10%) >2.8 m/s 72 (10%)
A velocity, peak mitral inflow during atrial contraction; E velocity, peak mitral inflow in early diastole; e0, peak mitral annular velocity in
early diastole; PV S/D ratio, ratio of systolic and diastolic velocities in the pulmonary vein; RV, right ventricle; RVSP, RV systolic pressure;
TDI, tissue Doppler imaging; TR, tricuspid regurgitation.
Summary statistics are median (interquartile range) or n (%).
aAmerican Society of Echocardiography and European Association of Cardiovascular Imaging guidelines for the evaluation of diastolic
function.10
bAtherosclerosis Risk in Communities study 95th percentile limit.3
cAmerican Society of Echocardiography guidelines for assessment of the right heart.17 RV dysfunction defined as ≥mild dysfunction, and
RV dilatation defined as ≥mild dilatation.9
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diastolic, abnormalities predicted HF (Table 4). ROC curve
analysis confirmed the results of Cox regression analysis, with
statistically significant C statistics for ARIC criteria for struc-
tural, systolic, and diastolic abnormalities, but only for
ASE/EACVI structural and systolic, and not diastolic, abnormal-
ities (Figure 2).
Stage B heart failure and incident symptomatic
heart failure
Given the higher prevalence of structural and systolic abnor-
malities for ARIC criteria, 2.5-fold more participants had ARIC
SBHF (n = 1988) than ASE/EACVI SBHF (n = 804). The C statistics
Figure 1 Venn diagram demonstrating the numbers of SCREEN-HF participants (men and women) with structural, systolic, and diastolic abnormalities,
according to the ASE/EACVI and ARIC guidelines, and the number (%) in each category who subsequently developed heart failure (HF). BSA, body sur-
face area; LAV, left atrial volume; LVEDV, LV end diastolic volume; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; WMA, wall motion
abnormality.
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for ARIC SBHF [0.60, 95% confidence interval (CI): 0.57, 0.64]
and ASE/EACVI SBHF (0.66, 95% CI: 0.61, 0.71) were not signif-
icantly different (P = 0.07 at 4 years), although ARIC SBHF
criteria achieved 81% sensitivity for prediction of incident
symptomatic HF, in comparison with 55% for ASE/EACVI SBHF
criteria, at the expense of lower specificity (Figure 2).
Addition of diastolic dysfunction to Stage B heart
failure criteria
Nearly twice as many participants had DD according to the
ASE/EACVI (n = 2848) than the ARIC criteria (n = 1619), and
addition of DD to SBHF criteria increased the total number
with any structural, systolic, or diastolic abnormality to 2913
(91% of participants) according to ASE/EACVI criteria and
2462 (77% of participants) according to ARIC criteria (Figure 1).
Addition of ASE/EACVI DD to ASE/EACVI SBHF criteria in-
creased the sensitivity of prediction of symptomatic HF to
97%, at the expense of reduced specificity (9%), and reduc-
tion in the C statistic to 0.52 (95% CI: 0.50, 0.54,
P < 0.0001 in comparison with ASE/EACVI SBHF criteria),
whereas addition of ARIC DD to ARIC SBHF criteria increased
sensitivity to 94%, without change in the C statistic (0.59, 95%
CI: 0.57, 0.61), which was higher than for combined
ASE/EACVI SBHF and DD criteria (P < 0.0001, Figure 2).
Addition of longitudinal strain to Stage B heart
failure criteria
Of the 1401 participants with LS measurement, 45 developed
symptomatic HF and 373 were classified as SBHF by
ASE/EACVI criteria, which included 26 (58%) of the 45 partic-
ipants who developed HF. This sensitivity of 58% was similar
to the sensitivity of 55% for ASE/EACVI SBHF criteria applied
to the whole cohort (Figure 2). Addition of ARIC LS criteria
(>14.7% for men, >15.2% for women) to ASE/EACVI
SBHF criteria increased the number with abnormality to 386
but did not identify additional participants who developed
symptomatic HF. Addition of LS >18% to ASE/EACVI SBHF
criteria increased the number with abnormality to 522 and
identified an additional six participants who developed symp-
tomatic HF, bringing the number to 32 (sensitivity 71%).
ARIC criteria classified 723 of the 1401 participants with LS
measurement as SBHF. Participants with ARIC SBHF included
35 of the 45 with LS measurement who developed symptom-
atic HF (sensitivity 78%), similar to the sensitivity of 81% for
ARIC SBHF criteria applied to the whole cohort (Figure 2). Ad-
dition of ARIC LS criteria (>14.7% for men, >15.2% for
women) to ARIC SBHF criteria increased the number with ab-
normality to 897 but did not identify additional participants
who developed symptomatic HF. Addition of LS >18% to
ARIC SBHF criteria increased the number with abnormality
to 938 and identified one additional participant who devel-
oped HF, bringing the number to 36 (sensitivity 80%).
Discussion
Both the ASE/EACVI and ARIC criteria identified a high
prevalence of echocardiographic abnormalities in this
community-based Australian cohort ≥60 years of age with
CVD risk factors, and both ASE/EACVI and ARIC SBHF
criteria (cardiac structural or systolic abnormalities) pre-
dicted symptomatic HF. In contrast to previous studies that
examined the prediction of a composite of HF hospitaliza-
tion or death,3 or a composite of new onset HF and cardio-
vascular death,5 we examined the prediction of incident
symptomatic HF using models adjusted for the competing
risk of death,19,20 and most cases of incident HF were
Table 4 Cox regression: univariate and multivariable subdistribution hazard ratios
Parameter Univariate hazard ratios Multivariable hazard ratios
(95% CI) P values (95% CI) P values
ASE/EACVI criteria
Age (per decade) 2.68 (2.03, 3.54) <0.0001 2.33 (1.68, 3.24) <0.0001
Male gender 1.37 (0.96, 1.95) 0.085
Structural abnormality 3.27 (2.17, 4.93) <0.0001 2.19 (1.42, 3.27) 0.0004
Systolic abnormality 5.58 (3.77, 8.27) <0.0001 3.82 (2.43, 6.01) <0.0001
Diastolic abnormality 1.48 (0.69, 3.19) 0.31
ARIC criteria
Age (per decade) 2.68 (2.03, 3.54) <0.0001 2.23 (1.62, 3.05) <0.0001
Male gender 1.37 (0.96, 1.95) 0.085
Structural abnormality 3.16 (2.00, 4.99) <0.0001 2.40 (1.50, 3.83) 0.0003
Systolic abnormality 2.48 (1.68, 3.64) <0.0001 1.81 (1.19, 2.74) 0.0056
Diastolic abnormality 5.35 (3.14, 9.12) <0.0001 3.47 (1.94, 6.21) <0.0001
ARIC, Atherosclerosis Risk in Communities; ASE/EACVI, American Society of Echocardiography and European Association of Cardiovascular
Imaging; CI, confidence interval.
Hazard ratios were calculated using a semiparametric proportional hazards model for the subdistribution of the competing risk of
death.19 The ASE/EACVI and ARIC criteria for structural, systolic, and diastolic abnormality are described in Figure 1.
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diagnosed in the ambulant setting. We also showed that
the addition of DD, but not LS, to SBHF criteria improved
the prediction of symptomatic HF according to ARIC
criteria, but not according to ASE/EACVI criteria.
The different performance of ASE/EACVI and ARIC SBHF
criteria in predicting symptomatic HF in SCREEN-HF partici-
pants may have been due in part to the different ages of
the populations from which these criteria were derived.
The age of our cohort (median 71 years) more closely
resembled that of the ARIC study (median 75 years),3
whereas the ASE/EACVI guideline cut points were
determined in younger populations.7 We were unable to
define cut points for the SCREEN-HF cohort because none
were free of CVD risk factors.
Our finding that ARIC criteria for LVH, based on
LVM/height2.7, identified more than twice as many SCREEN-
HF participants with structural abnormality than ASE/EACVI
criteria for LVH based on LVM/BSA was in agreement with
previous studies demonstrating that normalization of LVM
to BSA underestimates LVH prevalence in obese and over-
weight hypertensive subjects, who comprised the majority
of SCREEN-HF participants.21–24 In addition, ARIC criteria
Figure 2 C statistics, sensitivities, specificities, positive (PPV) and negative (NPV) predictive values for the prediction of symptomatic HF by structural,
systolic, and diastolic abnormalities, and their combination, according to ASE/EACVI (Panel A) and ARIC criteria (Panel B). C statistics were calculated
from the receiver operating characteristic curve for 4 years follow-up after echocardiography, adjusted for competing risk of death.20 Sensitivity, spec-
ificity, PPV, and NPV were calculated for complete follow-up.
*
P< 0.0001 in comparison with ASE/EACVI SBHF criteria (Panel A) and in comparison with
combined SBHF and DD according to ARIC criteria (Panel B). The C statistic for combined ARIC SBHF and DD criteria was not statistically significantly
different from that for ARIC SBHF alone.
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identified 3.5-fold more SCREEN-HF participants with systolic
dysfunction than ASE/EACVI criteria, due to the higher LVEF
cut points for ARIC criteria. Consequently, ARIC criteria classi-
fied 2.5-fold more SCREEN-HF participants as SBHF than
ASE/EACVI criteria, thereby achieving higher sensitivity for
the prediction of symptomatic HF while maintaining similar
C indices.
The identification of nearly twice as many SCREEN-HF par-
ticipants with DD according to ASE/EACVI than ARIC criteria
was largely due to the lower e0 cut points of the ARIC criteria.
Our findings support the conclusion of Shah et al. that e0
values below the ASE/EACVI cut points, but above the ARIC
cut points, are largely prognostically benign25 and support
the use of the age-specific ARIC cut points for e0.
Some authors have used alternative definitions of SBHF.
For example, Yang et al. defined SBHF as at least one of
LVM/BSA >115 g/m2 for men or >95 g/m2 for women,
LAV/BSA >34 mL/m2, average E/e0 >13, and LS >18%.5
Wang et al. used a similar definition except that the LS cut
point was >16%.6 Neither definition included LVEF.5,6 Yang
et al. reported a sensitivity of 82% and specificity of 41% for
the prediction of symptomatic HF by their SBHF algorithm in
asymptomatic patients ≥65 years of age with at least one HF
risk factor,5 which is comparable with the 81% sensitivity and
39% specificity we obtained in the SCREEN-HF cohort for ARIC
SBHF criteria alone. There were, however, differences in
study design and event rates between the study of Yang
et al. and the SCREEN-HF study. Unlike Yang et al., we did
not exclude any participant because of poor images, AF, or
known coronary artery disease. Moreover, despite these ex-
clusions, Yang et al. reported an HF incidence rate of ~100
per 1000 person years, which was ~nine-fold higher than
we observed in the SCREEN-HF cohort.5
In contrast to the studies of Yang et al. and Wang et al.,5,6
we found that LS made little contribution to the prediction of
symptomatic HF when added to either ASE/EACVI or ARIC
SBHF criteria. The importance of this observation is that LVEF
is an established echocardiographic parameter that can be
measured in almost all patients, whereas reliable LS measure-
ment may not be possible in the same high proportion of
echocardiographic examinations. Moreover, use of an LS cut
point is problematic because echocardiographic equipment
from different manufacturers has different normal values
and there is no consensus about the cut points that define
abnormal LS.7
Strengths and limitations of the study
The strengths of our study include the diagnosis of HF in a
predominantly ambulant setting and the long duration of ob-
servation before HF diagnosis. Our outcome data were for
HF, and not a composite of HF and death, as used in previous
studies.3,25 We enrolled a cohort ≥60 years of age with CVD
risk factors in order to achieve sufficient events during
follow-up. However, we excluded individuals known at base-
line to have LVEF <50% or significant valve abnormality be-
cause such individuals have well-recognized HF risk, and our
aim was to identify otherwise unrecognized HF risk in a com-
munity cohort. The inclusion criteria with respect to age and
CVD risk factors, and the SCREEN-HF cohort comprising vol-
unteers who were predominantly members of a health fund,
may be cause for caution in the generalization of our findings
to the general community. However, the SCREEN-HF cohort
was not that dissimilar to the general Australian population
aged ≥60 years; of Australians aged 65–74 years, 70% have
hypertension,26 17% have diabetes,27 38.2% of men and
32.7% of women are obese,28 5% have AF,29 and 53% have
CVD,30 and our findings are therefore likely to be applicable
to the general community.
Conclusions and implications
Both the ASE/EACVI and ARIC criteria demonstrated a high
prevalence of echocardiographic abnormalities in an Austra-
lian cohort ≥60 years of age with CVD risk factors, and SBHF
criteria (cardiac structural or systolic abnormalities) predicted
symptomatic HF. Age-specific ARIC DD criteria, but not
ASE/EACVI DD criteria, predicted symptomatic HF, and addi-
tion of age-specific ARIC DD criteria to ARIC SBHF criteria im-
proved prediction of symptomatic HF in asymptomatic
individuals with CVD risk factors. Addition of LS to
ASE/EACVI or ARIC SBHF criteria did not improve prediction
of symptomatic HF.
Acknowledgements
We thank all SCREEN-HF study participants and the study
nurses, echocardiographers, and administrative staff for their
invaluable contribution.
Conflict of interest
Bupa Australia was involved in study design, recruitment of
participants, and funding but was not involved in data collec-
tion, analysis or interpretation, or writing of the article. Bupa
Australia had no control or influence over the decision to sub-
mit the final manuscript for publication.
J.M.Ca. has received payments from Pfizer, Servier, Bayer,
and Alphapharm for lectures. U.B. was an employee of Bupa
Australia. D.L. has received honoraria from Pfizer, Sanofi,
Astra-Zeneca, Abbott, Bayer, MSD, GSK, Novartis, and
Nycomed. S.S. has received unrestricted educational grants
from Schering Plough and Boehringer Ingelheim and was
Structural heart disease 755
ESC Heart Failure 2019; 6: 747–757
DOI: 10.1002/ehf2.12449
Principal Investigator of the Novartis sponsored Valsartan In-
tensified Primary Care Reduction of Blood Pressure (VIPER-
BP) study. H.K. received support from Novartis, Bristol-Myers
Squibb, and Ardian/Medtronic. D.L.P. has received payment
from Servier for sitting on their advisory board and from
Boehringer Ingelheim, CSL, Merck Sharp & Dohme, and
Sanofi Aventis for lectures. D.J.C. has received payments from
the Australasian Renin Academy for lectures.
Funding
This work was supported by Bupa Australia, with subse-
quent support from the National Health and Medical
Research Council of Australia (GTN0559010, GTN1044619,
GTN1092642, GTN0395508 to D.J.C., GTN1045862,
GTN1136372 to C.M.R., GTN1041796 to S.S., GTN0620241
to J.M.Co., GNT0519456 to M.M.), the National Heart
Foundation of Australia (G 07M 3198), the Diabetes
Australia Research Trust (Y15G-CAMD), The University of
Melbourne, St. Vincent’s Hospital Melbourne, St. Vincent’s
Institute of Medical Research, and the Victorian Govern-
ment’s Operational Infrastructure Support Program.
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Characteristics on enrolment (Visit 1) of SCREEN-HF
participants who subsequently attended for echocardiogra-
phy and those who did not
Figure S1. Flow chart of numbers of individuals invited to par-
ticipate in the SCReening Evaluation of the Evolution of New
Heart Failure (SCREEN-HF) study who were subsequently en-
rolled and attended Visit 1 and subsequent echocardiography
(Visit 2).
References
1. Yancy CW, Jessup M, Bozkurt B, Butler
J, Casey DE Jr, Drazner MH, Fonarow
GC, Geraci SA, Horwich T, Januzzi JL,
Johnson MR, Kasper EK, Levy WC,
Masoudi FA, McBride PE, McMurray
JJ, Mitchell JE, Peterson PN, Riegel B,
Sam F, Stevenson LW, Tang WH, Tsai
EJ, Wilkoff BL, American College
of Cardiology F, American Heart
Association Task Force on Practice G.
2013 ACCF/AHA guideline for the
management of heart failure: a report
of the American College of Cardiology
Foundation/American Heart Associa-
tion Task Force on Practice Guidelines.
J Am Coll Cardiol 2013; 62: e147–e239.
2. Huffman MD, Berry JD, Ning H, Dyer
AR, Garside DB, Cai X, Daviglus ML,
Lloyd-Jones DM. Lifetime risk for heart
failure among white and black Ameri-
cans: cardiovascular lifetime risk pooling
project. J Am Coll Cardiol 2013; 61:
1510–1517.
3. Shah AM, Claggett B, Loehr LR, Chang
PP, Matsushita K, Kitzman D, Konety S,
Kucharska-Newton A, Sueta CA, Mosley
TH, Wright JD, Coresh J, Heiss G, Fol-
som AR, Solomon SD. Heart failure
stages among older adults in the com-
munity: the atherosclerosis risk in com-
munities study. Circulation 2017; 135:
224–240.
4. Gong FF, Campbell DJ, Prior DL.
Noninvasive cardiac imaging and the
prediction of heart failure progression
in preclinical Stage A/B subjects.
JACC Cardiovasc Imaging 2017; 10:
1504–1519.
5. Yang H, Negishi K, Wang Y, Nolan M,
Saito M, Marwick TH. Echocardio-
graphic screening for non-ischaemic
stage B heart failure in the community.
Eur J Heart Fail 2016; 18: 1331–1339.
6. Wang Y, Yang H, Huynh Q, Nolan M,
Negishi K, Marwick TH. Diagnosis of
nonischemic Stage B heart failure in
type 2 diabetes mellitus: optimal param-
eters for prediction of heart failure.
JACC Cardiovasc Imaging 2018; 11:
1390–1400.
7. Lang RM, Badano LP, Mor-Avi V, Afilalo
J, Armstrong A, Ernande L,
Flachskampf FA, Foster E, Goldstein
SA, Kuznetsova T, Lancellotti P, Muraru
D, Picard MH, Rietzschel ER, Rudski L,
Spencer KT, Tsang W, Voigt JU.
Recommendations for cardiac chamber
quantification by echocardiography in
adults: an update from the American
Society of Echocardiography and the
European Association of Cardiovascular
Imaging. J Am Soc Echocardiogr 2015;
28: 1–39, e14.
8. Eng J, McClelland RL, Gomes AS,
Hundley WG, Cheng S, Wu CO, Carr JJ,
Shea S, Bluemke DA, Lima JA. Adverse
left ventricular remodeling and age
assessed with cardiac MR imaging: the
multi-ethnic study of atherosclerosis.
Radiology 2016; 278: 714–722.
9. Lang RM, Bierig M, Devereux RB,
Flachskampf FA, Foster E, Pellikka PA,
Picard MH, Roman MJ, Seward J,
Shanewise JS, Solomon SD, Spencer
KT, Sutton MS, Stewart WJ. Recommen-
dations for chamber quantification: a re-
port from the American Society of
Echocardiography’s Guidelines and
Standards Committee and the Chamber
Quantification Writing Group, devel-
oped in conjunction with the European
Association of Echocardiography, a
branch of the European Society of Cardi-
ology. J Am Soc Echocardiogr 2005; 18:
1440–1463.
10. Nagueh SF, Smiseth OA, Appleton CP,
Byrd BF 3rd, Dokainish H, Edvardsen T,
Flachskampf FA, Gillebert TC, Klein AL,
Lancellotti P, Marino P, Oh JK, Popescu
BA, Waggoner AD. Recommendations
for the evaluation of left ventricular dia-
stolic function by echocardiography: an
update from the American Society of
Echocardiography and the European As-
sociation of Cardiovascular Imaging. J
Am Soc Echocardiogr 2016; 29: 277–314.
11. Campbell DJ, Coller JM, Gong FF,
McGrady M, Prior DL, Boffa U, Shiel L,
Liew D, Wolfe R, Owen AJ, Krum H,
Reid CM. Risk factor management in a
contemporary Australian population at
increased cardiovascular disease risk. In-
tern Med J 2018; 48: 688–698.
12. Gong FF, Jelinek MV, Castro JM, Coller
JM, McGrady M, Boffa U, Shiel L, Liew
756 J.M. Coller et al.
ESC Heart Failure 2019; 6: 747–757
DOI: 10.1002/ehf2.12449
D, Wolfe R, Stewart S, Owen AJ, Krum
H, Reid CM, Prior DL, Campbell DJ. Risk
factors for incident heart failure with
preserved or reduced ejection fraction,
and valvular heart failure, in a
community-based cohort. Open Heart
2018; 5: e000782.
13. Campbell DJ, Gong FF, Jelinek MV, Cas-
tro JM, Coller JM, McGrady M, Boffa U,
Shiel L, Wang BH, Liew D, Wolfe R,
Stewart S, Owen AJ, Krum H, Reid CM,
Prior DL. Prediction of incident heart
failure by serum amino-terminal pro-B-
type natriuretic peptide level in a
community-based cohort. Eur J Heart
Fail 2019; 21: 449–459.
14. McMurray JJ, Adamopoulos S, Anker
SD, Auricchio A, Bohm M, Dickstein K,
Falk V, Filippatos G, Fonseca C, Gomez-
Sanchez MA, Jaarsma T, Kober L, Lip
GY, Maggioni AP, Parkhomenko A,
Pieske BM, Popescu BA, Ronnevik PK,
Rutten FH, Schwitter J, Seferovic P,
Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A. ESC Guidelines for
the diagnosis and treatment of acute
and chronic heart failure 2012: The Task
Force for the Diagnosis and Treatment of
Acute and Chronic Heart Failure 2012 of
the European Society of Cardiology. De-
veloped in collaboration with the Heart
Failure Association (HFA) of the ESC.
Eur Heart J 2012; 33: 1787–1847.
15. Nagueh SF, Appleton CP, Gillebert TC,
Marino PN, Oh JK, Smiseth OA,
Waggoner AD, Flachskampf FA, Pellikka
PA, Evangelista A. Recommendations for
the evaluation of left ventricular
diastolic function by echocardiography.
J Am Soc Echocardiogr 2009; 22:
107–133.
16. Bonow RO, Cheitlin MD, Crawford MH,
Douglas PS. Task Force 3: valvular heart
disease. J Am Coll Cardiol 2005; 45:
1334–1340.
17. Rudski LG, Lai WW, Afilalo J, Hua L,
Handschumacher MD, Chandrasekaran
K, Solomon SD, Louie EK, Schiller NB.
Guidelines for the echocardiographic
assessment of the right heart in adults:
a report from the American Society of
Echocardiography endorsed by the Euro-
pean Association of Echocardiography, a
registered branch of the European Soci-
ety of Cardiology, and the Canadian So-
ciety of Echocardiography. J Am Soc
Echocardiogr 2010; 23: 685–713.
18. Rosner A, Barbosa D, Aarsaether E,
Kjonas D, Schirmer H, D’Hooge J. The in-
fluence of frame rate on two-dimensional
speckle-tracking strain measurements: a
study on silico-simulated models and im-
ages recorded in patients. Eur Heart J
Cardiovasc Imaging 2015; 16: 1137–1147.
19. Fine JP, Gray RJ. A proportional hazards
model for the subdistribution of a com-
peting risk. J Am Stat Assoc 1999; 94:
496–509.
20. Blanche P, Dartigues JF, Jacqmin-Gadda
H. Estimating and comparing time-
dependent areas under receiver operat-
ing characteristic curves for censored
event times with competing risks. Stat
Med 2013; 32: 5381–5397.
21. de Simone G, Daniels SR, Devereux RB,
Meyer RA, Roman MJ, de Divitiis O, Al-
derman MH. Left ventricular mass and
body size in normotensive children and
adults: assessment of allometric rela-
tions and impact of overweight. J Am
Coll Cardiol 1992; 20: 1251–1260.
22. Gosse P, Jullien V, Jarnier P, Lemetayer
P, Clementy J. Echocardiographic defini-
tion of left ventricular hypertrophy in
the hypertensive: which method of in-
dexation of left ventricular mass? J
Hum Hypertens 1999; 13: 505–509.
23. Cuspidi C, Meani S, Negri F, Giudici V,
Valerio C, Sala C, Zanchetti A, Mancia
G. Indexation of left ventricular mass
to body surface area and height to allo-
metric power of 2.7: is the difference
limited to obese hypertensives? J Hum
Hypertens 2009; 23: 728–734.
24. Kuznetsova T, Haddad F, Tikhonoff V,
Kloch-Badelek M, Ryabikov A, Knez J,
Malyutina S, Stolarz-Skrzypek K, Thijs
L, Schnittger I, Wu JC, Casiglia E,
Narkiewicz K, Kawecka-Jaszcz K,
Staessen JA, European Project On Genes
in Hypertension I. Impact and pitfalls of
scaling of left ventricular and atrial
structure in population-based studies. J
Hypertens 2016; 34: 1186–1194.
25. Shah AM, Claggett B, Kitzman D,
Biering-Sorensen T, Jensen JS, Cheng
S, Matsushita K, Konety S, Folsom AR,
Mosley TH, Wright JD, Heiss G, Solo-
mon SD. Contemporary assessment of
left ventricular diastolic function in
older adults: the atherosclerosis risk in
communities study. Circulation 2017;
135: 426–439.
26. Australian Institute of Health and Wel-
fare. Cardiovascular disease, diabetes
and chronic kidney disease—Australian
facts: risk factors. Cardiovascular, Diabe-
tes and Chronic Kidney Disease; Series
No 4, Cat no CDK 4. Canberra: AIHW;
2015.
27. Australian Institute of Health and Wel-
fare. Diabetes compendium. https://
www.aihw.gov.au/reports/diabetes/
diabetes-compendium/contents/
how-many-australians-have-diabetes
(21 May 2018).
28. Australian Institute of Health and
Welfare. An interactive insight into over-
weight and obesity in Australia. https://
www.aihw.gov.au/reports/overweight-
obesity/interactive-insight-into-
overweight-and-obesity/contents/
how-many-people-are-overweight-or-
obese (21 May 2018).
29. Ball J, Thompson DR, Ski CF, Carrington
MJ, Gerber T, Stewart S. Estimating the
current and future prevalence of atrial
fibrillation in the Australian adult popu-
lation. Med J Aust 2015; 202: 32–35.
30. Australian Institute of Health and
Welfare. Cardiovascular health compen-
dium. https://www.aihw.gov.au/
reports/heart-stroke-vascular-disease/
cardiovascular-health-compendium/
contents/how-many-australians-have-
cardiovascular-disease (21 May 2018).
Structural heart disease 757
ESC Heart Failure 2019; 6: 747–757
DOI: 10.1002/ehf2.12449
